Antibiotic Dosing in Patients with Acute Kidney Injury

Journal of Intensive Care Medicine

Volumn 31, Issue 3, 2016, Pages 164-176

  Lewis, Susan J ^a   Mueller, Bruce A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

acute kidney injury; antibiotics; pharmacodynamics; pharmacokinetics; renal replacement therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; CASE REPORT; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; FLUID RESUSCITATION; HUMAN; INTENSIVE CARE UNIT; MORTALITY; OXYGEN SATURATION; PATIENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; REVIEW; SEPTIC SHOCK; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; MICROBIOLOGY; MULTIPLE ORGAN FAILURE; PRACTICE GUIDELINE; PROCEDURES; SEPSIS;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MULTIPLE ORGAN FAILURE; PRACTICE GUIDELINES AS TOPIC; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 84961321419     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066614555490     Document Type: Review

References (164)

1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39 (2): 165-228.
2. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients. JAMA. 2005; 294 (7): 813-818.
3. Silvester W, Bellomo R, Cole L,. Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia. Crit Care Med. 2001; 29 (10): 1910-1915.
4. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006; 10 (3): R73.
5. Waikar SS, Liu KD, Chertow GM,. The incidence and prognostic significance of acute kidney injury. Curr Opin Nephrol Hypertens. 2007; 16 (3): 227-236.
6. Bagshaw SM, Uchino S, Kellum JA, et al. Association between renal replacement therapy in critically ill patients with severe acute kidney injury and mortality. J Crit Care. 2013; 28 (6): 1011-1018.
7. Aronoff GR, Aronoff JR,. Drug prescribing in kidney disease: can't we do better? Am J Kidney Dis. 2014; 63 (3): 382-383.
8. Farag A, Garg AX, Li L, Jain AK,. Dosing errors in prescribed antibiotics for older persons with CKD: a retrospective time series analysis. Am J Kidney Dis. 2014; 63 (3): 422-428.
9. Micek ST, Welch EC, Khan J, et al. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gram-negative bacteremia. J Hosp Med. 2011; 6 (7): 405-410.
10. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR,. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29 (7): 1303-1310.
11. Martin GS, Mannino DM, Eaton S, Moss M,. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348 (16): 1546-1554.
12. Angus DC, Pereira CA, Silva E,. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets. 2006; 6 (2): 207-212.
13. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units(EPIC II study). JAMA. 2009; 302 (21): 2323-2329.
14. Quenot JP, Binquet C, Kara O, et al. The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit Care. 2013; 17 (2): R65.
15. Kollef MH, Sherman G, Ward S, Fraser VJ,. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115 (2): 462-474.
16. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH,. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000; 118 (1): 146-155.
17. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D,. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003; 115 (7): 529-535.
18. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH,. Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011; 39 (1): 46-51.
19. Taccone FS, Laterre PF, Dugernier T, et al. Insufficient B-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010; 14 (4): R126.
20. Seyler L, Cotton F, Taccone FS, et al. Recommended B-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011; 15 (3): R137.
21. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial B-lactam concentrations in select critically ill patients. Chest. 2012; 142 (1): 30-39.
22. Binder L, Schwörer H, Hoppe S, et al. Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit. 2013; 35 (1): 63-70.
23. Stechmiller JK, Treloar D, Allen N,. Gut dysfunction in critically ill patients: a review of the literature. Am J Crit Care. 1997; 6 (3): 204-209.
24. Boucher BA, Wood GC, Swanson JM,. Pharmacokinetic changes in critically illness. Crit Care Clin. 2006; 22 (2): 255-271.
25. Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J,. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012; 141 (5): 1327-1336.
26. Roberts DJ,. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. 2013; 9 (9): 1067-1084.
27. Nguyen NQ, Ng MP, Chapman M, Fraser RJ, Holloway RH,. The impact of admission diagnosis on gastric emptying in critically ill patients. Crit Care. 2007; 11 (1): R16.
28. Mueller BA, Brierton DG, Abel SR, Bowman L,. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother. 1994; 38 (9): 2101-2105.
29. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med. 1998; 24 (10): 1047-1051.
30. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991; 114 (9): 755-757.
31. Piscitelli SC, Goss TF, Wilton J, D'Andrea DT, Goldstein H, Schentag JJ,. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991; 35 (9): 1765-1771.
32. Chin TWF, Loeb M, Fong IW,. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995; 39 (8): 1671-1675.
33. Dörffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular- weight heparin to patients on vasopressors. Lancet. 2002; 359 (9309): 849-850.
34. Haas CE, Nelsen JL, Raghavendran K, et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma. 2005; 59 (6): 1336-1343.
35. Parrillo JE,. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993; 328 (20): 1471-1477.
36. Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 1990; 16 (5): 303-306.
37. Gous AG, Dance MD, Lipman J, Luyt DK, Mathivha R, Scribante J,. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care. 1995; 23 (6): 678-682.
38. Tang GJ, Tang JJ, Lin BS, Kong CW, Lee TY,. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand. 1999; 43 (7): 726-730.
39. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA,. Experience with a once- daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002; 28 (7): 936-942.
40. Del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominquez-Gil A, Sanchez Navarro A,. Pharmacokinetic/pharmacodynamics analysis of vancomycin in ICU patients. Intensive Care Med. 2007; 33 (2): 279-285.
41. Taccone FS, Hites M, Beumier M, Scolletta S, Jacobs F,. Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. Curr Infect Dis Rep. 2011; 13 (5): 406-415.
42. Vilay AM, Grio M, DePestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011; 39 (1): 19-25.
43. Wenisch JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2012; 67 (4): 977-983.
44. Bauer SR, Salem C, Connor MJ Jr, et al. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol. 2012; 7 (3): 452-457.
45. Khadzhynov D, Slowinski T, Lieker I, et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther. 2011; 49 (11): 656-665.
46. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H,. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004; 48 (8): 2799-2807.
47. Botha FJ, van der Bijl P, Seifart HI, Parkin DP,. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med. 1996; 22 (5): 443-446.
48. Tormo C, Abad FJ, Ronchera-Oms CL, Parra V, Jimenez NV,. Critically-ill patients receiving total parenteral nutrition show altered amikacin pharmacokinetics. Clinical Nutrition. 1995; 14 (4): 254-259.
49. Ronchera-Oms CL, Tormo C, Ordovas JP, Abad J, Jimenez NV,. Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther. 1995; 20 (5): 253-258.
50. Payen D, de Pont AC, Sakr Y, et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008; 12 (3): R74.
51. Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009; 76 (4): 422-427.
52. Grams ME, Estrella MM, Coresh J, Brower RG, Liu KD, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol. 2011; 6 (5): 966-973.
53. Teixeira C, Garzotto F, Piccinni P, et al. Fluid balance and urine volume are independent predictors of mortality in acute kidney injury. Crit Care. 2013; 17 (1): R14.
54. SAFE Study Investigators. Finfer S, Bellomo R, McEvoy S, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the Saline versus Albumin Fluid Evaluation (SAFE) study. BMJ. 2006; 333 (7577): 1044.
55. Roberts JA, Federico P, Lipman J,. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013; 52 (1): 1-8.
56. Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother. 2007; 59 (2): 277-284.
57. Eyler RF, Vilay AM, Nader AM, et al. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. Antimicrob Agents Chemother. 2014; 58 (3): 1320-1326.
58. Andreasen F,. The effect of dialysis on the protein binding of drugs in the plasma of patients with acute renal failure. Acta Pharmacol Toxicol. 1974; 34 (4): 284-294.
59. Mussche MM, Belpaire FM, Bogaert MG,. Plasma protein binding of phenylbutazone during recovery from acute renal failure. Eur J Clin Pharmacol. 1975; 9 (1): 69-71.
60. Vilay AM, Churchwell MD, Mueller BA,. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care. 2008; 12 (6): 235.
61. Lalande L, Charpiat B, Leboucher G, Tod M,. Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet. 2014; 53 (6): 521-532.
62. Kirwan CJ, MacPhee IA, Lee T, Holt DW, Philips BJ,. Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med. 2012; 38 (1): 76-84.
63. Sun H, Frassetto L, Benet LZ,. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006; 109 (1-2): 1-11.
64. Jones EM, McMullin CM, Hedges AJ, et al. The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother. 1997; 40 (1): 121-124.
65. Macias WL, Mueller BA, Scarim SK,. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther. 1991; 18 (4): 451-458.
66. Mueller BA, Scarim SK, Macias WL,. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis. 1993; 21 (2): 172-179.
67. Tegeder I, Bremer F, Oelkers R, et al. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1997; 41 (12): 2540-2545.
68. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human patients. Clin Pharmacol Ther. 1988; 43 (5): 565-570.
69. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J,. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999; 34 (3): 886-892.
70. Churchwell MD, Mueller BA,. Drug dosing during continuous renal replacement therapy. Semin Dial. 2009; 22 (2): 185-188.
71. Pasko DA, Churchwell MD, Salama NN, Mueller BA,. Longitudinal hemodiafilter performance in modeled continuous renal replacement therapy. Blood Purif. 2011; 32 (2): 82-88.
72. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J,. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009; 37 (7): 2268-2282.
73. Heintz BH, Matzke GR, Dager WE,. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009; 29 (5): 562-577.
74. Eyler RF, Mueller BA,. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol. 2011; 7 (4): 226-235.
75. Kielstein JT, Burkhardt O,. Dosing of antibiotics in critically ill patients undergoing renal replacement therapy. Curr Pharm Biotechnol. 2011; 12 (12): 2015-2019.
76. Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller PD, Olsen KM,. Antibiotic dosing during sustained low-efficiency dialysis: special consideration in adult critically ill patients. Crit Care Med. 2011; 39 (3): 560-570.
77. Scoville BA, Mueller BA,. Medication dosing in critically ill patients with acute kidney injury with renal replacement therapy. Am J Kideny Dis. 2013; 61 (3): 490-500.
78. Mueller BA, Smoyer WE,. Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy. Clin Pharmacol Ther. 2009; 86 (5): 479-482.
79. Vesconi S, Cruz DN, Fumagalli R, et al. DOse REsponse Multicentre International collaborative Initiative (DO-RE-MI Study Group): delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit Care. 2009; 13 (2): R57.
80. VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008; 359 (1): 7-20.
81. RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, et al. Intensity of continuous renal replacement therapy in critically ill patients. N Eng J Med. 2009; 361 (17): 1627-1638.
82. Kielstein JT, David S,. Pro: renal replacement trauma or paracelsus 2.0. Nephrol Dial Transplant. 2013; 28 (11): 2728-2733.
83. Covajes C, Scolletta S, Penaccini L, et al. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents. 2013; 41 (3): 261-266.
84. Roberts JA, Mehta RL, Lipman J,. Sustained low efficiency dialysis allows rational renal replacement therapy, but dose it allow rational drug dosing? Crit Care Med. 2011; 39 (3): 602-603.
85. Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med. 2004; 32 (12): 2437-2442.
86. Arzuaga A, Maynar J, Gascón AR, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol. 2005; 45 (2): 168-176.
87. Kielstein JT, Czock D, Schopke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med. 2006; 34 (1): 51-56.
88. Burkhardt O, Joukhadar C, Traunmuller F, Hadem J, Welte T, Kielstein JT,. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother. 2008; 61 (1): 224-225.
89. Wilson FP, Berns JS,. Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). Clin Nephrol. 2012; 77 (4): 329-331.
90. Zoller M, Maier B, Hornuss C, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014; 18 (4): R148.
91. Owens RC, Shorr AF,. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamics strategies. Am J Health-Sys Pharm. 2009; 66 (4): S23-S30.
92. Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care. 2006; 10 (1): R26.
93. Langgartner J, Vasold A, Glück T, Reng M, Kees F,. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med. 2008; 34 (6): 1091-1096.
94. Saugel B, Nowack MC, Hapfelmeier A, et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care. 2013; 28 (1): 9-13.
95. Beumier M, Roberts JA, Kabtouri H, et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother. 2013; 68 (12): 2859-2865.
96. Lodise TP, Lomaestro B, Drusano G,. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended infusion dosing strategy. Clin Infect Dis. 2007; 44 (3): 357-363.
97. Kielstein JT, Engbers C, Bode-Boeger SM, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant. 2010; 25 (5): 1537-1541.
98. Mueller BA, Scoville BA,. Adding to the armamentarium: antibiotic dosing in extended dialysis. Clin J Am Soc Nephrol. 2012; 7 (3): 373-375.
99. Taccone FS, de Backer D, Laterre PF, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2011; 37 (6): 5.
100. Truong J, LEvkovich BJ, Padiglione AA,. Simple approach to improving vancomycin dosing in intensive care: a standardized loading dose results in earlier therapeutic levels. Intern Med J. 2012; 42 (1): 23-29.
101. Kamel Mohamed OH, Wahba IM, Watnick S, et al. Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen. Clin J Am Soc Nephrol. 2007; 2 (4): 694-699.
102. Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA,. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008; 3 (2): 355-361.
103. Veistein A, Venisse N, Badin J, Pinsard M, Robert R, Dupuis A,. Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered. Antimicrob Agents Chemother. 2013; 57 (2): 977-982.
104. Roberts JA, Field J, Visser A, et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother. 2010; 54 (9): 3635-3640.
105. Calbo E, Garau J,. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community acquired respiratory tract infections. Respiration. 2005; 72 (6): 561-571.
106. Scaglione F, Paraboni L,. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther. 2006; 4 (3): 479-490.
107. McKinnon PS, Paladino JA, Schentag JJ,. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008; 31: 345-351.
108. Valtonen M Tiula, Takkunen O, Backman JT, Neuvonen PJ,. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2001; 48 (6): 881-885.
109. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ,. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infec Dis. 2013; 56 (2): 272-282.
110. Chant C, Leung A, Friedrich JO,. Optimal dosing of antibiotics in critically ill patients using continuous/extended infusion: a systematic review and meta-analysis. Crit Care. 2013; 17 (6): R279.
111. Moriyama B, Henning SA, Neuhauser MM, Danner RL, Walsh TJ,. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother. 2009; 43 (7): 1324-1337.
112. Joy MS, Matzke GR, Frye RF, Palevsky PM,. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis. 1998; 31 (6): 1019-1027.
113. DelDot ME, Lipman J, Tett SE,. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004; 58 (3): 259-268.
114. Moore RD, Lietman PS, Smith CR,. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987; 155 (1): 93-99.
115. Martinez MN, Papich MG, Drusano GL,. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012; 56 (6): 2795-2805.
116. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003; 112 (2): 275-285.
117. Trotman RL, William JC, Shoemaker DM, Salzer WL,. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005; 41 (8): 1159-1166.
118. Matsuo H, Hayashi J, Ono K, et al. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality. Antimicrob Agents Chemother. 1997; 41 (12): 2597-2601.
119. Teigen MM, Duffull S, Dang L, Johnson DW,. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol. 2006; 46 (11): 1259-1267.
120. Gentamicin [package insert]. Lake Forest, IL: Hospira, Inc; August 2005. http://www.hospira.com/Images/EN-1004-32-5467-1.pdf. Accessed March 12, 2014.
121. Ryan DM, Cars O,. A problem in the interpretation of beta-lactam antibiotic levels in tissues. J Antimicrob Chemother. 1983; 12 (3): 281-284.
122. Schentag JJ, Heller AS, Hardy BG, Wels PB,. Antibiotic penetration in liver infection: a case of tobramycin failure responsive to moxalactam. Am J Gastroenterol. 1983; 78 (10): 641-644.
123. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001; 29 (2): 385-391.
124. Zeitlinger MA, Erovic BM, Sauermann R, Georgopoulos A, Müller M, Joukhadar C,. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. J Antimicrob Chemother. 2005; 56 (4): 703-708.
125. Klekner A, Bagyi K, Bognar L, Gaspar A, Andrasi M, Szabo J,. Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia. J Clin Microbiol. 2006; 44 (9): 3418-3421.
126. Stolle LB, Plock N, Joukhadar C, et al. Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis. Scand J Infect Dis. 2008; 40 (1): 24-29.
127. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008; 46 (6): 862-867.
128. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46 (2): 193-200.
129. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A,. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166 (19): 2138-2144.
130. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacist. Clin Infect Dis. 2009; 49 (3): 325-327.
131. Kullar R, McClellan I, Geriak M, Sakoulas G,. Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis. Pharmacotherapy. 2014; 34 (6): 582-589.
132. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32 (6): 470-485.
133. Klevens RM, Edwards JR, Gaynes RP,. The impact of antimicrobial-resistant, health care- associated infections on mortality in the United States. Clin Infect Dis. 2008; 47 (7): 927-930.
134. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48 (1): 1-12.
135. Peters NK, Dixon DM, Holland SM, Fauci AS,. The research agenda of the national institute of allergy and infectious diseases for antimicrobial resistance. J Infect Dis. 2008; 197 (8): 1087-1093.
136. Barth RH, DeVincenzo N,. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int. 1996; 50 (3): 929-936.
137. Taber SS, Mueller BA,. Drug-associated renal dysfunction. Crit Care Clin. 2006; 22 (2) 357-374.
138. Kane-Gill SL, Kirisci L, Verrico MM, Rothschild JM,. Analysis of risk factors for adverse drug events in critically ill patients. Crit Care Med. 2012; 40 (3): 823-828.
139. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistin sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009; 48 (12): 1724-1728.
140. Kwon JA, Lee JE, Huh W, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents. 2010; 35 (5): 473-477.
141. Schentag JJ, Cerra FB, Plaut ME,. Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrob Agents Chemother. 1982; 21 (5): 721-726.
142. Zager RA,. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis associated acute renal failure. Am J Kid Dis. 1992; 20 (3): 223-230.
143. Van Hal, Paterson DL, Lodise TP,. Systematic review and meta-analysis of vancomycin- induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013; 57 (2): 734-744.
144. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS,. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984; 100 (3): 352-357.
145. Lodise TP, Lomaestro B, Graves J, Drusano GL,. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52 (4): 1330-1336.
146. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL,. Relationship between initial vancomycin concentration time profile and nephrotoxicity. Clin Infect Dis. 2009; 49 (4): 507-514.
147. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB,. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010; 123 (12): 1143-1149.
148. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011; 55 (12): 5475-5479.
149. Cano EL, Haque NZ, Welch VL, et al. Incidence of Nephrotoxicity and Association With Vancomycin Use in Intensive Care Unit Patients With Pneumonia: Retrospective Analysis of the IMPACT-HAP Database. Clin Ther. 2012; 34 (1): 149-157.
150. Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN,. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993; 167 (1): 173-179.
151. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL,. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999; 43 (7): 1549-1555.
152. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A,. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007; 45 (15): 753-760.
153. Calandra GB, Brown KR, Grad LC, Ahonkhai VI, Wang C, Aziz MA,. Review of adverse experiences and tolerability in the first 2516 patients treated with imipenem/cilastatin. Am J Med. 1985; 78 (6A): 73-78.
154. Hellinger WC, Brewer NS,. Carbapenems and monobactams: imipenem, meropenem and aztreonam. Mayo Clin Proc. 1999; 74 (4): 420-434.
155. Norrby SR,. Carbapenems in serious infections: a risk benefit assessment. Drug Saf. 2000; 22 (3): 191-194.
156. Norrby SR, Newell PA, Faukner KL, Lesky W,. Safety profile of meropenem international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother. 2005; 36 (suppl A): 207-223.
157. Nicolau DP,. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008; 9 (1): 23-37.
158. Martinez-Rodriguez JE, Barriga FJ, Santamaria J, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med. 2001; 111 (2): 115-119.
159. Grill MF, Maganti R,. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008; 42 (12): 1843-1850.
160. Chapuis TM, Giannoni E, Majcherczyk PA, et al. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care. 2010; 14 (2): R51.
161. Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA,. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013; 17 (6): R264.
162. Bagshaw SM,. Short- and long-term survival after acute kidney injury. Nephrol Dial Transplant. 2008; 23 (7): 2126-2128.
163. Schiffl H, Fischer R,. Five-year outcomes of severe acute kidney injury requiring renal replacement therapy. Nephrol Dial Transplant. 2008; 23 (7): 2235-2241.
164. Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med. 1987; 107 (6): 900-909.